Hypoxic-Ischemic Encephalopathy (HIE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Hypoxic-Ischemic Encephalopathy (HIE) Market Outlook

Thelansis’s “Hypoxic-Ischemic Encephalopathy (HIE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypoxic-Ischemic Encephalopathy (HIE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hypoxic-Ischemic Encephalopathy (HIE) Overview

Hypoxic-ischemic encephalopathy (HIE) is a neurological syndrome that presents immediately after birth after a perinatal asphytic episode. It occurs due to oxygen deprivation in the brain, arterial hypoxemia or cerebral ischemia, or both. Alterations in alertness characterize it, with decreased ability to awaken and maintain muscle tone, reduced motor responses, and reactivity. HIE is a leading cause of neonatal death and permanent disability. It contributes significantly to the health burden regarding years of life lost and years lived with disability. In addition to the critical role that asphyxia plays in perinatal mortality, it is estimated that over one million newborns who survive it each year develop cerebral palsy, epilepsy, learning disabilities, and other developmental problems. It is currently the only standard therapy for HIE and is a safe and effective intervention for reducing mortality and significant disability in survivors.

• The incidence of Hypoxic-ischemic encephalopathy (HIE) ranges from 4% to 6.2% of total live birth, and the risk of death at 10% to 20% in neonates with moderate HIE and >60% in those with severe HIE.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: